. 2018 Apr 23;14:1093–1099. doi: 10.2147/NDT.S147874
© 2018 Frau et al. This work is published and licensed by Dove Medical Press Limited
The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
Figure 2.
B-cell lines that are targeted and spared by the action of ocrelizumab.